Zai Lab Limited
Zai Lab Limited (HKSE: 9688) is trading at HK$19.92, about ₹244 at today's HKD/INR rate, as of 28 Sep 2026, 4:08 AM ET, up 0.40% today. Indian residents can buy Zai Lab from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$19.57
Today's high
HK$20.34
52 week low
HK$12.31
52 week high
HK$27.28
9688 opened at HK$19.89, closed previously at HK$19.84, and has traded between HK$12.31 and HK$27.28 over the past 52 weeks.
About
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
Key statistics
Avg. volume
9.62M
Market cap
HK$22.49B
P/E Ratio
-14.57
Price-to-sales ratio
6.38
Enterprise value
$2.51B
Free cash flow yield
-4.70%
Debt-to-equity ratio
0.42
Return on equity
-27.40%
ROIC
-29.28%
Beta
0.78
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
$460.84M
Earnings per share
-$0.16
Free cash flow
-$159.13M
Net profit margin
-41.86%
Gross margin
56.47%
EBITDA
-$205.89M
Revenue growth
15.50%
Similar securities
This is not an investment recommendation
How to buy Zai Lab from India
Indian residents can buy Zai Lab shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Zai Lab and place an order
Find Zai Lab by name or by its ticker, 9688, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Zai Lab trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Zai Lab position in HKD and INR. Zai Lab pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Zai Lab from India
Trading and taxes when buying Zai Lab from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneZai Lab does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Zai Lab stock?
Yes. Zai Lab (9688) has been listed on the Hong Kong Stock Exchange since 2020, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Zai Lab share cost in rupees?
One Zai Lab share is HK$19.92 — about ₹244 at an HKD/INR rate of 12.24 on 27 Sep 2026. Both the Zai Lab price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Zai Lab from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Zai Lab?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Zai Lab shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Zai Lab price. Paasa issues a capital-gains statement for your return.
Does Zai Lab pay a dividend?
No. Zai Lab does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Zai Lab from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Zai Lab a Hong Kong SAR China company, and does that change how it is taxed?
Zai Lab trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Zai Lab trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Zai Lab shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Zai Lab holding, its cost and its closing value.
How do I sell Zai Lab and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.